215 related articles for article (PubMed ID: 21047493)
1. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
Dretzke J; Round J; Connock M; Tubeuf S; Pennant M; Fry-Smith A; Hulme C; McCabe C; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
[TBL] [Abstract][Full Text] [Related]
2. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
5. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
Bond M; Hoyle M; Moxham T; Napier M; Anderson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():69-74. PubMed ID: 19804692
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
Huse DM; von Mehren M; Lenhart G; Joensuu H; Blanke C; Feng W; Finkelstein S; Demetri G
Clin Drug Investig; 2007; 27(2):85-93. PubMed ID: 17217313
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of advanced hepatocellular carcinoma.
Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
[TBL] [Abstract][Full Text] [Related]
12. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
13. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
17. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
18. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).
Mabasa VH; Taylor SC; Chu CC; Moravan V; Johnston K; Peacock S; Knowling M
J Oncol Pharm Pract; 2008 Sep; 14(3):105-12. PubMed ID: 18524863
[TBL] [Abstract][Full Text] [Related]
19. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.
Essat M; Cooper K
Int J Cancer; 2011 May; 128(9):2202-14. PubMed ID: 21387287
[TBL] [Abstract][Full Text] [Related]
20. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J; Gong JF; Wu AW; Shen L
Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
